Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.38 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2441220 | 1.00 | TDP1 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL7343637 | 1.00 | TDP1 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL8762939 | 1.00 | TDP1 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL8761967 | 0.98 | CHRNA7 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL10366437 | 0.98 | CHRNA7 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL8761961 | 0.98 | CHRNA7 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL11465447 | 0.98 | CHRNA7 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL10366436 | 0.98 | CHRNA7 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL10366438 | 0.98 | CHRNA7 (0.41) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL13463493 | 0.95 | CHRNB4 (0.37) | TDP1CYP2D6MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| US-7294647-B2 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1112252-A4 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-RE38133-E1 | N-Arylalkylenecarbonyl-N-methyl-benzylamine derivatives; analgesics, opioid agonists, antiinflammatory agents | ADOLOR CORPORATION | 2003-06-03 | — | — | US | disclosed |
| US-4663343-A | ANAGESICS, DIURETICS | WARNER-LAMBERT COMPANY (US) | 1987-05-05 | — | — | US | disclosed |
| US-4656182-A | ANALGESICS, DIURETICS, PSYCHOTHERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0110869-B1 | THIENYLACETIC-ACID AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEROF AND PROCESS FOR THEIR PREPARATION | Laevosan-Gesellschaft m.b.H. (AT) | 1987-03-18 | — | — | EP | disclosed |
| US-4598087-A | DIURETICS; ANALGESICS, PSYCHOTHERAPEUTICS | WARNER-LAMBERT COMPANY (US) | 1986-07-01 | — | — | US | disclosed |
| US-4579863-A | Substituted trans-1,2-diaminocyclohexyl amide compounds | WARNER-LAMBERT COMPANY (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0147085-A2 | Substituted trans-1.2-diaminocyclohexyl amide compounds | WARNER-LAMBERT COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0146297-A1 | Substituted trans-1,2-diaminocyclohexyl amide compounds | WARNER-LAMBERT COMPANY (US) | 1985-06-26 | — | — | EP | disclosed |
| US-4499286-A | Derivatives of thienylacetic acid amides and their pharmaceutically acceptable acid salts and a process for the preparation thereof | Leavoson-Gesellschaft m.b.H. & Co. KG (AT) | 1985-02-12 | — | — | US | disclosed |
| EP-0110869-A1 | Thienylacetic-acid amide derivatives, pharmaceutically acceptable salts therof and process for their preparation | Laevosan-Gesellschaft m.b.H. (AT) | 1984-06-13 | — | — | EP | disclosed |
| US-4145435-A | 2-AMINOCYCLOALIPHATIC AMIDE COMPOUNDS | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | TDP1 4215/4885CYP2D6 946/4885MEN1 4703/4885 |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | TDP1 4084/4885CYP2D6 659/4885MEN1 4734/4885 |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | TDP1 4486/4885CYP2D6 886/4885MEN1 4678/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | TDP1 4174/4885CYP2D6 541/4885MEN1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.